Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer

Dong Hui Cho, Se Kyung Lee, Sangmin Kim, Min Young Choi, Seung Pil Jung, Jeonghui Lee, Jiyoung Kim, Min Young Koo, Soo Youn Bae, Jung Han Kim, Jee Soo Kim, Kil Won Ho, Jeong Eon Lee, Seok Jin Nam, Jung Hyun Yang

Research output: Contribution to journalArticle

Abstract

Purpose: We analyzed the responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (NAC) and NAC combined with neoadjuvant human epidermal growth factor receptor-2 (HER2) targeted therapy (NCHTT). Methods: We retrospectively reviewed 59 patients with HER2 amplified locally advanced breast cancer among patients who were treated surgically after neoadjuvant therapy at Samsung Medical Center between 2005 and 2009. Thirty-one patients received conventional NAC and 28 patients received NCHTT. Pathologic responses were assessed according to response evaluation criteria in solid tumors (RECIST) guidelines. Results: Pathologic complete response (pCR) was achieved in 13 out of 28 patients treated with NCHTT and in 6 out of 31 patients treated with NAC alone (46.4% vs. 19.4%, respectively, P = 0.049). Breast conserving surgery (BCS) was more frequently performed in the NCHTT group than in the NAC only group (71.4% vs. 19.4%, P < 0.001). The 3-year recurrence-free survival (RFS) rate was 100% in the NCHTT group and 76.4% in the NAC group (P = 0.014). Together, NCHTT, type of operation (BCS vs. mastectomy) and pathologic nodal status were significant prognostic factors for RFS in univariate analysis. Conclusion: We found that NCHTT produced higher pCR rates than NAC alone in locally advanced breast cancer.

Original languageEnglish
Pages (from-to)273-280
Number of pages8
JournalJournal of the Korean Surgical Society
Volume84
Issue number5
DOIs
Publication statusPublished - 2013 May

Keywords

  • Breast neoplasms
  • ErbB-2
  • Neoadjuvant therapy
  • Response

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Cho, D. H., Lee, S. K., Kim, S., Choi, M. Y., Jung, S. P., Lee, J., Kim, J., Koo, M. Y., Bae, S. Y., Kim, J. H., Kim, J. S., Ho, K. W., Lee, J. E., Nam, S. J., & Yang, J. H. (2013). Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer. Journal of the Korean Surgical Society, 84(5), 273-280. https://doi.org/10.4174/jkss.2013.84.5.273